Early Intensive Lipid Lowering Therapy to Reverse Plaques in Adults with Familial Hypercholesterolemia Aged 18 to 50

What this Trial Is About

Researchers are studying whether plaques in young patients with familial hypercholesterolemia, specifically those under 50 years old, respond to early and intensive lipid lowering therapy. The goal is to see if this approach can lead to significant plaque reduction and slow coronary artery disease progression. This observational study focuses on adults diagnosed with this genetic condition who have elevated LDL cholesterol levels. The study does not involve specific treatment interventions but observes the effects of aggressive lipid lowering therapy already prescribed to participants. It will monitor changes in coronary artery disease over 40 weeks, focusing on plaque progression and characteristics. Researchers will assess both calcified and non-calcified plaques, as well as high-risk plaque counts and changes in pericoronary adipose tissue. Participants will undergo evaluations at the start and after 40 weeks, including imaging studies to measure plaque and tissue changes. The main outcome is the progression of coronary artery disease, with secondary outcomes examining detailed plaque features. The study is led by the Academisch Medisch Centrum - Universiteit van Amsterdam and will continue until April 2027, involving adults aged 18 to 50 with familial hypercholesterolemia and elevated LDL cholesterol.

Plaque Reversal With Early, Aggressive Lipid Lowering Therapy